Auszug
Das verhornende und das nichtverhornende Plattenepithelkarzinom der Cervix uteri sind mit ca. 80% am häufigsten, gefolgt von dem Adenokarzinom der Cervix uteri mit ca. 20%. ätiologisch gesehen ist eine Infektion der Zervix mit high-risk humanen Papillomaviren (zumeist HPV-Typ 16, 18, seltener 31,33, 45, 51, 52 oder 56) Voraussetzung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ackermann S, Beckmann MW, Altgassen C (2004) Moderne operative Ansätze in der Therapie des Zervixkarzinoms. Gynäkologe 37: 669–675
Beckmann MW, Ackermann S, Hoern LC et al. (2006) Zervixkarzinom. In: Kaufmann M, Beckmann MW, Emons G et al. (ntHrsg) Aktuelle Empfehlungen der Arbeitsgemeinschaft Gynäkologische Onkologie. Zuckschwerdt, München,S 140–178
Beckmann MW, Mehlhorn G, Thiel F, Breuel C, Fasching PA, Ackermann S (2005) Therapiefortschritte beim primären Zervixkarzinom. Deutsches Ärzteblatt 14: A979–A986
Benedetti-Panici P, Greggi S, Colombo A et al. (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20(1): 179–188
Chang TC, Lai CH, Hong JH et al. (2000) Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 18(8): 1740–1747
Dargent D (2000) Uteruserhaltende Radikaloperationen des Zervixkarzinoms. Gynäkologe 33: 276–285
Dargent D, Enria R(2003) Laparoscopic assessment of the sentinel lymph nodes in early cervical cancer. Techniquepreliminary results and future developments. Crit Rev Oncol Hematol 48(3): 305–310
Long HJ 3rd, Bundy BN, Grendys EC jr et al. (2005) Randomized phase III trial of cisplatin with or without topotecan i n carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21): 4626–4633
Morris M, Eifel PJ, Lu J et al. (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med 340(15): 1137–1143
Peters WA, Liu PY, Barrett RJ et al. (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Clin Oncol 18(8): 1606–1613
Piver MS, Rutledge F, Smith JP(1974) Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44(2): 265–272
Shueng PW, Hsu WL, Jen YM, Wu CJ, Liu HS(1998) Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 40(4): 889–896
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Thiel, F.C., Mehlhorn, G., Ackermann, S., Beckmann, M.W. (2007). Zervixkarzinom. In: Therapiehandbuch Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-30098-4_40
Download citation
DOI: https://doi.org/10.1007/978-3-540-30098-4_40
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-30097-7
Online ISBN: 978-3-540-30098-4
eBook Packages: Medicine (German Language)